Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201520162017201820192020
Sales-0,132,6156,1106228
EBITDA-146-245-323-380-328-234
Operating profit (EBIT)-148-248-329-390-367-275
Pre-Tax Profit (EBT)-146-246-318-227-358-256
Net income-146-246-302-227-364-265
P/E ratio-28,3-11,3-6,51-14,6-10,0-14,2
EPS ( $ )-3,96-6,21-7,12-4,39-6,41-4,52
Dividend per Share ( $ )------
Yield------
Reference price ( $ )112.1870.3146.3864.1464.1464.14
Announcement Date02/25/2016
09:05pm
02/16/2017
09:05pm
02/20/2018
09:46pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201520162017201820192020
Debt------
Finance437498244255266221
Operating income (EBITDA)-146-245-323-380-328-234
Leverage
(Debt/EBITDA)
------
Capital Expenditure4,9610,22,793,003,004,00
Book Value Per Share (BVPS)13,7 $11,8 $8,68 $10,4 $8,28 $7,26 $
Cash Flow per Share-2,88 $-4,07 $-5,98 $-3,92 $-3,46 $-0,80 $
Announcement Date02/25/2016
09:05pm
02/16/2017
09:05pm
02/20/2018
09:46pm
---
Balance Sheet Analysis
Assessed data source :
© 2018 Thomson Reuters
Financial Ratios

Size 2018e 2019e
Capitalization 3 219 M$ -
Entreprise Value (EV) 2 963 M$ 2 952 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS)
Capitalization / Revenue 57,3x 30,3x
EV / Revenue 52,8x 27,8x
EV / EBITDA -7,81x -9,00x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 6,16x 7,74x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) -696% -346%
operating Leverage (Delta EBIT / Delta Sales) - 0,07x
Net Margin (Net Profit / Revenue) -405% -343%
ROA (Net Profit / Asset) -57,0% -41,6%
ROE (Net Profit / Equities) -48,6% -59,0%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   5,34% 2,83%
Cash Flow / Sales -350% -164%
Capital Intensity (Assets / Sales) 7,11x 8,24x
Financial Leverage (Net Debt / EBITDA) 0,67x 0,81x
EPS & Dividend